Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
137 hedge funds and large institutions have $557M invested in Infinity Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 59 increasing their positions, 44 reducing their positions, and 21 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 44
16% more call options, than puts
Call options by funds: $3.56M | Put options by funds: $3.07M
2.46% more ownership
Funds ownership: 100.88% → 103.34% (+2.5%)
3% less funds holding
Funds holding: 141 → 137 (-4)
19% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 21
20% less capital invested
Capital invested by funds: $692M → $557M (-$135M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$24.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$11.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.13M |
| 4 |
Renaissance Technologies
New York
|
+$6.81M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$6.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$19.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$14.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.82M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$6.13M |
| 5 |
Millennium Management
New York
|
-$5.58M |
INFI Hedge Fund Activity: Q2 2015 in Review
137 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q2 2015, worth a combined $557M — down 20% from $692M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of INFI and 17 opened new positions — a net loss of 4 holders — while 44 trimmed existing stakes and 59 added.
The largest buyer was Goldman Sachs, adding an estimated $24.5M. The largest seller was Deerfield Management, cutting an estimated $19.3M.
- 137 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q2 2015, down from 141 in Q1 2015.
- Funds reported $557M of Infinity Pharmaceuticals, Inc. stock for Q2 2015, down 20% quarter-over-quarter.
- 17 funds opened new Infinity Pharmaceuticals, Inc. positions in Q2 2015 and 21 closed out, a net change of -4 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q2 2015 was Goldman Sachs, an estimated $24.5M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q2 2015 was Deerfield Management, an estimated $19.3M sold.
Based on aggregated 13F filings for Q2 2015.